Skip To Content

Study ID: Rebiotix Punch SOS

Title:

An Open-label Safety Assessment of Rebiotix RBX2660 (microbiota suspension) for the Treatment of Recurrent Clostridium difficile Infection

Location:
Fargo Region
Principal Investigator:
Avish Nagpal, MD
Disease:
Other
Stage:
Unknown
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.